keyboard_arrow_up

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Alcobra Ltd Amarantus Bioscience Holdings, Inc. Arbor Pharmaceuticals, LLC. Cerecor Inc. Collegium Pharmaceutical, Inc. Curemark, LLC DURECT Corporation Eli Lilly and Company H. Lundbeck A/S Hisamitsu Pharmaceutical Co., Inc. Integrative Research Laboratories Sweden AB Intra-Cellular Therapies, Inc. KemPharm, Inc. Merck & Co., Inc. Mnemosyne Pharmaceuticals, Inc. Neos Therapeutics, Inc. NeuroDerm Ltd. Otsuka Holdings Co., Ltd. P2D Bioscience Polleo Pharma Limited Reviva Pharmaceuticals Inc. Samyang Biopharmaceuticals Corporation Shire Plc Signature Therapeutics, Inc Sunovion Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc. Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Tris Pharma, Inc. Vernalis Plc ention Deficit Hyperactivity Disorder (ADHD) - Th Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###